» Articles » PMID: 15961552

Biological Variation of Total Prostate-specific Antigen: a Survey of Published Estimates and Consequences for Clinical Practice

Overview
Journal Clin Chem
Specialty Biochemistry
Date 2005 Jun 18
PMID 15961552
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The objectives of this study were to determine whether a single result for total prostate-specific antigen (tPSA) can be used confidently to guide the need for prostate biopsy and by how much serial tPSA measurements must differ to be significant. tPSA measurements include both analytical and biological components of variation. The European Group on Tumor Markers conducted a literature survey to determine both the magnitude and impact of biological variation on single, the mean of replicate, and serial tPSA measurements.

Methods: The survey yielded 27 studies addressing the topic, and estimates for the biological variation of tPSA could be derived from 12 of these studies.

Results: The mean biological variation was 20% in the concentration range 0.1-20 microg/L for men over 50 years. The biological variation means that the one-sided 95% confidence interval (CI) of the dispersion for a single tPSA result is approximately 33%. Three replicate samples with one analysis on each narrow the one-sided 95% CI for the mean concentration to approximately 20% and facilitate decisions on prostate biopsy. During monitoring of serial measurements, the change needed for significance is approximately 50% (P <0.05).

Conclusions: The biological variation of tPSA has implications for screening, diagnosis, and monitoring. Single measurements may not be sufficiently precise for screening and diagnosis. Replicate samples and calculation of the mean concentration may improve precision by reducing the dispersion. Monitoring of tPSA requires an estimate of either the change needed for significance or, alternatively, of the significance of the change.

Citing Articles

Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review.

von Eyben F, Kairemo K, Kapp D Biomedicines. 2024; 12(4).

PMID: 38672176 PMC: 11048591. DOI: 10.3390/biomedicines12040822.


Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels.

Kobayashi M, Kijima T, Yashi M, Kamai T Prostate Int. 2023; 11(1):27-33.

PMID: 36910897 PMC: 9995685. DOI: 10.1016/j.prnil.2022.08.001.


Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism.

Emery A, Moore S, Turner J, Campbell J Front Oncol. 2022; 12:788113.

PMID: 35359426 PMC: 8964011. DOI: 10.3389/fonc.2022.788113.


Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.

Nelson T, Javier-Desloges J, Deka R, Courtney P, Nalawade V, Mell L JAMA Netw Open. 2021; 4(5):e219452.

PMID: 33999164 PMC: 8129822. DOI: 10.1001/jamanetworkopen.2021.9452.


Biological variation of major gut-derived uremic toxins in the serum of healthy adult cats.

Summers S, Quimby J, Yao L, Hess A, Broeckling C, Lappin M J Vet Intern Med. 2021; 35(2):902-911.

PMID: 33537991 PMC: 7995407. DOI: 10.1111/jvim.16043.